Why the study?
What are the pharmacokinetics and safety of caudal ropivacaine 0.2% in infants and toddlers?
Population
20 male children undergoing inguinal hernia repair, grouped into 10 'infants' aged less than 1 year and 10…
Design
Cohort
Follow-up
2 hours
Authors
Loading...
Supports safe caudal ropivacaine use despite higher infant levels; leaves open optimal dosing refinements pending prospective trials.
What are the pharmacokinetics and safety of caudal ropivacaine 0.2% in infants and toddlers?
Caudal blockade using ropivacaine 0.2% 1 ml.kg-1 produces safe peak plasma concentrations in both infants and toddlers without clinical signs of toxicity.
Wulf et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: